Clinical Trial Update: Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC [Phase 2]

View source ↗

Summary

This update covers a Phase 2 neoadjuvant trial of gefitinib (Iressa) in patients with Stage I non-small cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: LUNG CANCER | Phase 2 | Status: COMPLETED